|
1
|
Falkson CB, Bezjak A, Darling G, et al;
Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in
Evidence-Based Care. The management of thymoma: a systematic review
and practice guideline. J Thorac Oncol. 4:911–919. 2009.
|
|
2
|
Harris K, Elsayegh D, Azab B, Alkaied H
and Chalhoub M: Thymoma calcification: Is it clinically meaningful?
World J Surg Oncol. 9:952011.
|
|
3
|
Okumura M, Fujii Y, Shiono H, Inoue M,
Minami M, Utsumi T, Kadota Y and Sawa Y: Immunological function of
thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen
Thorac Cardiovasc Surg. 56:143–150. 2008.
|
|
4
|
Okumura M, Inoue M, Kadota Y, Hayashi A,
Tokunaga T, Kusu T, Sawabata N and Shiono H: Biological
implications of thymectomy for myasthenia gravis. Surg Today.
40:102–107. 2010.
|
|
5
|
Müller-Hermelink HK and Marx A:
Pathological aspects of malignant and benign thymic disorders. Ann
Med. 31(Suppl 2): 5–14. 1999.
|
|
6
|
Hong YH, Kwon SB, Kim BJ, et al; Korean
Research Group for Neuromuscular Diseases. Prognosis of ocular
myasthenia in Korea: a retrospective multicenter analysis of 202
patients. J Neurol Sci. 273:10–14. 2008.
|
|
7
|
Romi F: Thymoma in myasthenia gravis: from
diagnosis to treatment. Autoimmune Dis. 2011:4745122011.
|
|
8
|
Vincent A, Palace J and Hilton-Jones D:
Myasthenia gravis. Lancet. 357:2122–2128. 2001.
|
|
9
|
Romi F, Bø L, Skeie GO, Myking A, et al:
Titin and ryanodine receptor epitopes are expressed in cortical
thymoma along with costimulatory molecules. J Neuroimmunol.
128:82–89. 2002.
|
|
10
|
Skeie GO, Bentsen PT, Freiburg A, Aarli JA
and Gilhus NE: Cell-mediated immune response against titin in
myasthenia gravis: evidence for the involvement of Th1 and Th2
cells. Scand J Immunol. 47:76–81. 1998.
|
|
11
|
McIntire JJ, Umetsu SE, Akbari O, Potter
M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT and DeKruyff RH:
Identification of Tapr (an airway hyperreactivity regulatory locus)
and the linked Tim gene family. Nat Immunol. 2:1109–1116. 2001.
|
|
12
|
McIntire JJ, Umetsu DT and DeKruyff RH:
TIM-1, a novel allergy and asthma susceptibility gene. Springer
Semin Immunopathol. 25:335–348. 2004.
|
|
13
|
Xu JR, Yang Y, Liu XM, Sun JY and Wang YJ:
Polymorphisms of the TIM-1 gene are associated with rheumatoid
arthritis in the Chinese Hui minority ethnic population. Genet Mol
Res. 11:61–69. 2012.
|
|
14
|
Vega-Carrascal I, Reeves EP and McElvaney
NG: The role of TIM-containing molecules in airway disease and
their potential as therapeutic targets. J Inflamm Res. 5:77–87.
2012.
|
|
15
|
Abbas AK, Murphy KM and Sher A: Functional
diversity of helper T lymphocytes. Nature. 383:787–793. 1996.
|
|
16
|
Ohtani H, Naruse TK, Iwasaki Y, Akari H,
Ishida T, Matano T and Kimura A: Lineage-specific evolution of
T-cell immunoglobulin and mucin domain 1 gene in the primates.
Immunogenetics. 64:669–678. 2012.
|
|
17
|
Seki M, Oomizu S, Sakata KM, et al:
Galectin-9 suppresses the generation of Th17, promotes the
induction of regulatory T cells, and regulates experimental
autoimmune arthritis. Clin Immunol. 127:78–88. 2008.
|
|
18
|
Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao
L, Ju Y, Zhang L, Sun W and Ma C: Expression of human TIM-1 and
TIM-3 on lymphocytes from systemic lupus erythematosus patients.
Scand J Immunol. 67:63–70. 2008.
|
|
19
|
Khademi M, Illés Z, Gielen AW, et al: T
Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1
molecules are differentially expressed on human Th1 and Th2 cells
and in cerebrospinal fluid-derived mononuclear cells in multiple
sclerosis. J Immunol. 172:7169–7176. 2004.
|
|
20
|
Sánchez-Fueyo A, Tian J, Picarella D, et
al: Tim-3 inhibits T helper type 1-mediated auto- and alloimmune
responses and promotes immunological tolerance. Nat Immunol.
4:1093–1101. 2003.
|
|
21
|
Ngiow SF, von Scheidt B, Akiba H, Yagita
H, Teng MW and Smyth MJ: Anti-TIM3 antibody promotes T cell
IFN-γ-mediated antitumor immunity and suppresses established
tumors. Cancer Res. 71:3540–3551. 2011.
|
|
22
|
Sakuishi K, Jayaraman P, Behar SM,
Anderson AC and Kuchroo VK: Emerging Tim-3 functions in
antimicrobial and tumor immunity. Trends Immunol. 32:345–349.
2011.
|
|
23
|
Rennert PD, Ichimura T, Sizing ID, Bailly
V, Li Z, Rennard R, McCoon P, Pablo L, Miklasz S, Tarilonte L and
Bonventre JV: T cell, Ig domain, mucin domain-2 gene-deficient mice
reveal a novel mechanism for the regulation of Th2 immune responses
and airway inflammation. J Immunol. 177:4311–4321. 2006.
|
|
24
|
Wang Z, Wang W, Chen Y and Wei D: T helper
type 17 cells expand in patients with myasthenia-associated
thymoma. Scand J Immunol. 76:54–61. 2012.
|
|
25
|
Chae SC, Park YR, Song JH, Shim SC, Yoon
KS and Chung HT: The polymorphisms of Tim-1 promoter region are
associated with rheumatoid arthritis in a Korean population.
Immunogenetics. 56:696–701. 2005.
|
|
26
|
Kaplan G, Totsuka A, Thompson P, Akatsuka
T, Moritsugu Y and Feinstone SM: Identification of a surface
glycoprotein on African green monkey kidney cells as a receptor for
hepatitis A virus. EMBO J. 15:4282–4296. 1996.
|
|
27
|
Feigelstock D, Thompson P, Mattoo P, Zhang
Y and Kaplan GG: The human homolog of HAVcr-1 codes for a hepatitis
A virus cellular receptor. J Virol. 72:6621–6628. 1998.
|
|
28
|
Ichimura T, Bonventre JV, Bailly V, Wei H,
Hession CA, Cate RL and Sanicola M: Kidney injury molecule-1
(KIM-1), a putative epithelial cell adhesion molecule containing a
novel immunoglobulin domain, is up-regulated in renal cells after
injury. J Biol Chem. 273:4135–4142. 1998.
|
|
29
|
Rodriguez-Manzanet R, DeKruyff R, Kuchroo
VK and Umetsu DT: The costimulatory role of TIM molecules. Immunol
Rev. 229:259–270. 2009.
|
|
30
|
de Souza AJ, Oriss TB, O’malley KJ, Ray A
and Kane LP: TIM-1 is expressed on in vivo-activated T cells and
provides a co-stimulatory signal for T cell activation. Proc Natl
Acad Sci USA. 102:17113–17118. 2005.
|
|
31
|
Binné LL, Scott ML and Rennert PD: Human
TIM-1 associates with the TCR complex and up-regulates T cell
activation signals. J Immunol. 178:4342–4350. 2007.
|
|
32
|
Nakae S, Iikura M, Suto H, Akiba H, Umetsu
DT, Dekruyff RH, Saito H and Galli SJ: Tim-1 and Tim-3 enhancement
of Th2 cytokine production by mast cells. Blood. 110:2565–2568.
2007.
|
|
33
|
Sizing ID, Bailly V, McCoon P, et al:
Epitope-dependent effect of anti-murine Tim-1 monoclonal antibodies
on T cell activity and lung immune responses. J Immunol.
178:2249–2261. 2007.
|
|
34
|
Kim HY, Eyheramonho MB, Pichavant M, et
al: A polymorphism in TIM1 is associated with susceptibility to
severe hepatitis A virus infection in humans. J Clin Invest.
121:1111–1118. 2011.
|
